Dulaglutide
Brand names: Trulicity
Part of: GLP-1 drugs
At a glance
- Medicare prescriptions, 2024
- 3,762,194
- Medicare drug cost
- $4.72B
- Average cost per prescription
- $1,254
- Clinicians who prescribed it
- 100,316
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
TRULICITY ® is indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.
From the FDA-approved prescribing information (label dated June 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: RISK OF THYROID C-CELL TUMORS In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined. TRULICITY is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with use of TRULICITY and inform them of symptoms of thyroid tumors (e.g., mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early…
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Family Medicine 30.6%
- Internal Medicine 22.7%
- Nurse Practitioners 20.6%
- Endocrinology & Diabetes 13.7%
- Physician Assistants 7.2%
- Geriatric Medicine 1.1%
- General Practice 1.1%
- Nephrology (Kidney) 0.5%
- Pharmacists 0.4%
- Hospitalist 0.4%
- Cardiology 0.3%
- Pediatrics 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 101% from 2019 to 2024.
Biggest change by state since 2019
- Puerto Rico +653%
- Wisconsin +268%
- Rhode Island +232%
- Colorado +221%
- Michigan +208%
- South Carolina (smallest change) +32%
- Tennessee (smallest change) +35%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
Industry payments about this drug
Drug makers reported $6,663 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Lilly USA, LLC $5,696
- Eli Lilly and Company $968
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
2 recalls since 2020
- Apr 2022 · Cardinal Health Inc. · Class II
TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions - Aug 2021 · Eli Lilly & Company · Class II
Labeling: Label error on declared strength - autoinjector devices labeled as 0.75 mg / 0.5 mL actually contain 1.5 mg / 0.5 mL of product.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Industry-funded trials
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.